The estimated Net Worth of Michel Detheux is at least $7.95 Million dollars as of 18 April 2022. Dr Detheux owns over 11,500 units of iTeos Therapeutics stock worth over $603,830 and over the last 4 years he sold ITOS stock worth over $6,511,822. In addition, he makes $833,750 as Pres und CEO & Director at iTeos Therapeutics.
Sign up
Dr Detheux ITOS stock SEC Form 4 insiders trading
Dr has made over 14 trades of the iTeos Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 11,500 units of ITOS stock worth $48,645 on 18 April 2022.
The largest trade he's ever made was selling 44,500 units of iTeos Therapeutics stock on 2 December 2021 worth over $1,982,030. On average, Dr trades about 10,533 units every 15 days since 2020. As of 18 April 2022 he still owns at least 37,763 units of iTeos Therapeutics stock.
You can see the complete history of Dr Detheux stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Michel Detheux biography
Dr. Michel Detheux is the Pres, CEO & Director at iTeos Therapeutics.
What is the salary of Dr Detheux?
As the Pres und CEO & Director of iTeos Therapeutics, the total compensation of Dr Detheux at iTeos Therapeutics is $833,750. There are no executives at iTeos Therapeutics getting paid more.
How old is Dr Detheux?
Dr Detheux is 54, he's been the Pres und CEO & Director of iTeos Therapeutics since . There are 1 older and 3 younger executives at iTeos Therapeutics. The oldest executive at iTeos Therapeutics, Inc. is Dr. Michel Detheux Ph.D., 55, who is the Pres, CEO & Director.
What's Dr Detheux's mailing address?
Michel's mailing address filed with the SEC is C/O ITEOS THERAPEUTICS, INC., 321 ARSENAL STREET, WATERTOWN, MA, 02472.
Insiders trading at iTeos Therapeutics
Over the last 4 years, insiders at iTeos Therapeutics have traded over $196,492,023 worth of iTeos Therapeutics stock and bought 4,975,000 units worth $95,182,800 . The most active insiders traders include Capital Management, L.P.Ra ..., Capital Management, L.P.Kol... und Aaron I. Davis. On average, iTeos Therapeutics executives and independent directors trade stock every 12 days with the average trade being worth of $1,817,279. The most recent stock trade was executed by Matthew Gall on 12 October 2023, trading 5,000 units of ITOS stock currently worth $41,850.
What does iTeos Therapeutics do?
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.
What does iTeos Therapeutics's logo look like?
Complete history of Dr Detheux stock trades at iTeos Therapeutics
iTeos Therapeutics executives and stock owners
iTeos Therapeutics executives and other stock owners filed with the SEC include:
-
Dr. Michel Detheux Ph.D.,
Pres, CEO & Director -
Dr. Michel Detheux,
Pres, CEO & Director -
Dr. Joanne Jenkins Lager M.D.,
Chief Medical Officer -
Matthew Gall,
Chief Financial Officer -
Philippe Brantegem,
Vice-Pres of HR -
Ryan Baker,
Head of Investor Relations -
Matthew A. Call M.B.A.,
Chief Operating Officer -
David Feltquate,
Chief Medical Officer -
Bio Ventures 2014, L.P.Evni...,
-
Capital Management, L.P.Kol...,
-
Capital, Llc Boxer Asset Ma...,
-
Aaron I. Davis,
-
Ann D Rhoads,
-
Ansbert Gadicke,
Director -
Derek Di Rocco,
Director -
David Hallal,
-
Detlev Biniszkiewicz,
Director -
Capital, Llc Boxer Asset Ma...,
-
Hauwermeiren Timothy Van,
-
Ansbertubs Oncology Impact ...,
-
Bio Ventures 2014, L.P.Mpm ...,
-
Matthew Roden,
Director -
Matthew Call,
Chief Operating Officer -
Yvonne Mc Grath,
Chief Scientific Officer -
Joanne Jenkins Lager,
Chief Medical Officer -
Robert Iannone,
-
Capital Management, L.P.Ra ...,
-
Bio Ventures 2014, L.P.Evni...,
-
Bioventures 2018, L.P.Mpm B...,
-
Ansbertubs Oncology Impact ...,
-
Ansbertubs Oncology Impact ...,
-
Capital, Llc Boxer Asset Ma...,
-
Capital, Llc Boxer Asset Ma...,
-
David K Lee,
-
Michel Detheux,
Chief Executive Officer -
Matthew Gall,
Chief Financial Officer -
Jill De Simone,
-
Tony W Ho,